Do a search on the AFM-Telethon website.
ILTOO Pharma and the European consortium MIROCALS have just announced the signing of a license agreement for the development of a low-dose Interleukin 2 as a potential treatment for amyotrophic lateral sclerosis (ALS). The AFM-Telethon helped finance this clinical study, which shows an improvement in patient survival.
Thank you to everyone: donors, volunteers mobilized throughout France and abroad, families, partners, personalities! Thanks to your mobilization on December 2 and 3, the Telethon 2022 raised 90,839,067 euros! This tremendous result - the best since 2016 - shows how much the French people support the families’ fight against rare diseases.
Because muscles are a major public health issue, AFM-Telethon and the Institute of Myology, an international center of expertise on muscles and their diseases, are carrying out a project for a Myology Foundation. In addition, to raise awareness on myology among the public, they are launching two events dedicated to this public health issue in June 2023: the Muscle Conferences and Muscle Week.
Their determination and expertise are at the origin of great scientific advances and major victories. Thanks to the researchers in the Telethon laboratories, children suffering from formerly incurable diseases have been saved.
Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has launched a pivotal clinical trial in Europe for treatment of Crigler-Najjar syndrome, a life threatening liver disease, in France, Italy and the Netherlands.
The AFM-Telethon sends you its best wishes for the New Year and wishes you a year 2023 full of color and joy!
The Téléthon 30-hour-long broadcast ended with donations totaling 78 051 091 euros. From Guebwiller to Cassis, Dijon, Lorient and Cap-Ferret, millions of people came together again for the Téléthon, this unique celebration with its thousands of events. A vital support for the families and researchers, “these saving lives maniacs” as Kev Adams called them. But while researchers’ victories multiply, all week-end long patients and their families reminded everyone of the urgency of finding new treatments.
"Advances in Charcot-Marie-Tooth (CMT) disease" is a new document, published by the French Muscular Dystrophy Association (AFM-Téléthon), which can be read and/or downloaded here.
You live abroad and want to play a part in the Telethon? Join the Telethon for French people abroad and help us break records of mobilization around the world!
During four days, from 12 to 15th of September, researchers, clinicians and myology experts have attended the seventh International Congress of Myology, organized by AFM-Téléthon, in Nice, France. A good opportunity to exchange and share knowledge about myology and innovative therapies. Let’s have a look back at Myology 2022 with our researchers’ video interviews.
AFM-Telethon wanted to formalise the objectives that clinical study protocols should pursue and the points of attention they call for concerning organisational and methodological aspects. This formalisation should help AFM members in their participation in protocols.
From September 12 to 17th, AFM-Telethon will hold two successive scientific congresses gathering close to 1000 international experts on myology and mitochondrial medicine at the Nice Acropolis Convention Centre. Registrations are open!
You are now on a website that is edited by the French Muscular Dystrophy Association (AFM-Téléthon), a 1901 law association of public utility. Its headquarters are based in Paris : AFM-Institut de Myologie, 47-83 boulevard de l’Hôpital, 75651 Paris Cedex 13.
AFM-Telethon has long struggled to defend the rights of patients, of people living with disabilities, and to obtain recognition for rare diseases. As a driver of research and innovation, it defends an ambitious national policy.
The AFM-Telethon has chosen to implement a strategy of public interest to benefit as many people as possible.